Navigation Links
ETEX Corporation Announces FDA Clearance of Small Size Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty
Date:4/27/2009

CAMBRIDGE, Mass., April 27 /PRNewswire/ -- ETEX Corporation, a leading orthopaedic biomaterials company, announced today FDA 510k clearance of 1cc and 2.5cc sizes of Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty to complement the existing 5cc and 10cc sizes. Both products are bone substitute materials based on ETEX's proprietary nanocrystalline calcium phosphate technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO )

Beta-bsm(TM) and Gamma-bsm(TM) set hard to provide an optimal osteoconductive scaffold that mimics the nanocrystalline structure of human bone. Smaller sizes were developed in direct response to the needs of the small bone market. Both hand and foot/ankle surgeons requested user friendly moldable and injectable materials that set fast, are drillable, provide high compressive strength and remodel into bone over time.

Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty are intended for use in filling bone voids or defects of the skeletal system (including extremities, pelvis, and spine) that are not intrinsic to the stability of the bone structure. ETEX's rapidly expanding product portfolio, including EquivaBone(TM), a hard-setting, certified osteoinductive product, is marketed through a growing independent distribution network.

Brian Ennis, CEO of ETEX Corporation, comments, "ETEX is proud of our product development approach, driven by direct customer input. We are excited to offer state of the art bone graft substitutes, formulated for optimal performance and patient outcomes, in sizes complimentary to extremity surgery."

About ETEX Corporation

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.


'/>"/>
SOURCE ETEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
2. Volcano Corporation Schedules First Quarter Conference Call, Webcast
3. WebReach, Inc. Becomes Mirth Corporation
4. Environmental Tectonics Corporation Exhibiting at the Annual Symposium on Advanced Wound Care and Wound Healing Society
5. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
6. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
7. General Patent Corporation Calls New Patent Reform Bill Harmful to Inventors and Entrepreneurs
8. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
9. Siemens Healthcare Announces Planned Collaboration with Harris Corporation
10. Environmental Tectonics Corporation Announces Participation at APWCA National Conference
11. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... TX (PRWEB) , ... February 17, 2017 , ... ... has officially opened for business in Hong Kong. , Nerium International is proud ... Formula, and Firming Body Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. ...
(Date:2/17/2017)... ... ... Academy of Model Aeronautics (AMA), the nation’s leading voice ... systems (UAS), are launching a joint program to promote safe and responsible drone ... efforts. , AMA and DJI will collaborate on other potential opportunities to mutually ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, 2017 ... on venture growth investments in biotechnology and medical ... Richardson , M.D. to Managing Director. ... He is a board observer at InfaCare Pharmaceutical ... investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals ...
(Date:2/16/2017)... Mass. , Feb. 16, 2017   Biostage, ... the "Company"), a biotechnology company developing bioengineered organ implants ... esophagus, bronchus and trachea, announced today the closing on ... of 20,000,000 shares of common stock and warrants to ... proceeds of $8.0 million. The offering was priced at ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):